Is Passage Bio Stock a Good Investment?
Passage Bio Investment Advice | PASG |
- Examine Passage Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Passage Bio's leadership team and their track record. Good management can help Passage Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Passage Bio's business and its evolving consumer preferences.
- Compare Passage Bio's performance and market position to its competitors. Analyze how Passage Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Passage Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Passage Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Passage Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Passage Bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Passage Bio Stock
Researching Passage Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 57.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.38. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Passage Bio recorded a loss per share of 20.4. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 14th of July 2025.
To determine if Passage Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Passage Bio's research are outlined below:
| Passage Bio had very high historical volatility over the last 90 days | |
| Passage Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Passage Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Financial Survey Abeona Therapeutics vs. Passage Bio |
Passage Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Passage Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Passage Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Passage Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Passage Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-12 | 2025-03-31 | -0.2233 | -0.25 | -0.0267 | 11 | ||
2024-08-08 | 2024-06-30 | -0.31 | -0.26 | 0.05 | 16 | ||
2024-05-14 | 2024-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2024-03-04 | 2023-12-31 | -0.4 | -0.3 | 0.1 | 25 | ||
2022-08-04 | 2022-06-30 | -0.83 | -0.73 | 0.1 | 12 | ||
2022-05-16 | 2022-03-31 | -0.89 | -0.79 | 0.1 | 11 | ||
2023-05-11 | 2023-03-31 | -0.5 | -0.63 | -0.13 | 26 | ||
2020-11-10 | 2020-09-30 | -0.76 | -0.63 | 0.13 | 17 |
Passage Bio Target Price Consensus
Passage target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Passage Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Passage analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Passage stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Passage Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPassage Bio Target Price Projection
Passage Bio's current and average target prices are 5.67 and 6.00, respectively. The current price of Passage Bio is the price at which Passage Bio is currently trading. On the other hand, Passage Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Passage Bio Target Price
Passage Bio Analyst Ratings
Passage Bio's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Passage Bio stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Passage Bio's financials, market performance, and future outlook by experienced professionals. Passage Bio's historical ratings below, therefore, can serve as a valuable tool for investors.Know Passage Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Passage Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Passage Bio backward and forwards among themselves. Passage Bio's institutional investor refers to the entity that pools money to purchase Passage Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fiduciary Trust Co | 2025-03-31 | 215 K | State Street Corp | 2025-03-31 | 156.8 K | Shay Capital Llc | 2025-03-31 | 146.7 K | Rbf Llc | 2025-03-31 | 142.8 K | Millennium Management Llc | 2025-03-31 | 136.2 K | Northern Trust Corp | 2025-03-31 | 112 K | Simplex Trading, Llc | 2025-03-31 | 82.3 K | Squarepoint Ops Llc | 2025-03-31 | 64.1 K | Two Sigma Investments Llc | 2025-03-31 | 47 K | Orbimed Advisors, Llc | 2025-03-31 | 7 M | Vestal Point Capital Lp | 2025-03-31 | 6.1 M |
Passage Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.69 M.Market Cap |
|
Passage Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.85) | (0.89) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (1.06) | (1.00) |
Determining Passage Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Passage Bio is a good buy. For example, gross profit margin measures Passage Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Passage Bio's profitability and make more informed investment decisions.
Evaluate Passage Bio's management efficiency
Passage Bio has return on total asset (ROA) of (0.3363) % which means that it has lost $0.3363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8373) %, meaning that it created substantial loss on money invested by shareholders. Passage Bio's management efficiency ratios could be used to measure how well Passage Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.66. The current Return On Capital Employed is estimated to decrease to -0.89. At this time, Passage Bio's Non Current Assets Total are most likely to increase significantly in the upcoming years. The Passage Bio's current Total Current Assets is estimated to increase to about 141.2 M, while Total Assets are projected to decrease to roughly 97.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.01 | 0.96 | |
| Tangible Book Value Per Share | 1.01 | 0.96 | |
| Enterprise Value Over EBITDA | (0.36) | (0.38) | |
| Price Book Value Ratio | 0.56 | 0.59 | |
| Enterprise Value Multiple | (0.36) | (0.38) | |
| Price Fair Value | 0.56 | 0.59 | |
| Enterprise Value | 22.2 M | 21.1 M |
Leadership at Passage Bio emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.67 |
Basic technical analysis of Passage Stock
As of the 23rd of July, Passage Bio holds the Coefficient Of Variation of 9417.35, semi deviation of 6.71, and Risk Adjusted Performance of 0.0185. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Passage Bio, as well as the relationship between them. Please check Passage Bio information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Passage Bio is priced some-what accurately, providing market reflects its current price of 5.67 per share. Given that Passage Bio has jensen alpha of (0.11), we recommend you to check out Passage Bio's recent market performance to make sure the company can sustain itself at a future point.Passage Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Passage Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Passage Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Passage Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Passage Bio's Outstanding Corporate Bonds
Passage Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Passage Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Passage bonds can be classified according to their maturity, which is the date when Passage Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Passage Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Passage Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0185 | |||
| Market Risk Adjusted Performance | 0.0804 | |||
| Mean Deviation | 6.17 | |||
| Semi Deviation | 6.71 | |||
| Downside Deviation | 7.03 | |||
| Coefficient Of Variation | 9417.35 | |||
| Standard Deviation | 8.1 | |||
| Variance | 65.67 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (1.44) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0704 | |||
| Maximum Drawdown | 40.89 | |||
| Value At Risk | (9.75) | |||
| Potential Upside | 15.95 | |||
| Downside Variance | 49.37 | |||
| Semi Variance | 45.05 | |||
| Expected Short fall | (6.87) | |||
| Skewness | 0.8817 | |||
| Kurtosis | 1.03 |
| Risk Adjusted Performance | 0.0185 | |||
| Market Risk Adjusted Performance | 0.0804 | |||
| Mean Deviation | 6.17 | |||
| Semi Deviation | 6.71 | |||
| Downside Deviation | 7.03 | |||
| Coefficient Of Variation | 9417.35 | |||
| Standard Deviation | 8.1 | |||
| Variance | 65.67 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (1.44) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0704 | |||
| Maximum Drawdown | 40.89 | |||
| Value At Risk | (9.75) | |||
| Potential Upside | 15.95 | |||
| Downside Variance | 49.37 | |||
| Semi Variance | 45.05 | |||
| Expected Short fall | (6.87) | |||
| Skewness | 0.8817 | |||
| Kurtosis | 1.03 |
Consider Passage Bio's intraday indicators
Passage Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Passage Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Passage Bio Corporate Filings
| 21st of July 2025 Other Reports | ViewVerify | |
8K | 14th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 26th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 16th of April 2025 Other Reports | ViewVerify |
Passage Stock media impact
There is far too much social signal, news, headlines, and media speculation about Passage Bio that are available to investors today. This information is accessible both publicly - through Passage Bio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Passage-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Passage Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Passage Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Passage Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Passage Bio alpha.
Passage Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Passage Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Passage Bio Corporate Management
| Sue Browne | Senior Development | Profile | |
| Simona King | CFO Sec | Profile | |
| JD Esq | General Secretary | Profile | |
| Gregory Fuest | Vice Marketing | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Kathleen Borthwick | Principal Finance | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Passage Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.